|
|
Vaccine Detail
|
gp100-Reactive Autologous Peripheral Blood Lymphocyte Vaccine |
| Vaccine Information |
- Vaccine Name: gp100-Reactive Autologous Peripheral Blood Lymphocyte Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007488
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: gp100
- gp100 (PMEL)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- MLANA
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- S100A9
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to the same patient to target tumor sites expressing gp100. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. (NCIT_C38124).
|
| Host Response |
|
|
| References |
NCIT_C38124: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38124]
|
|
